Teva Challenges Shire's Adderall XR Patent

Law360, New York (February 23, 2005, 12:00 AM EST) -- Israeli generics maker Teva Pharmaceuticals has initiated a challenge against the patent rights to U.K. drug maker Shire Pharmaceuticals Group PLC’s blockbuster anti-hyperactivity treatment Adderall XR.

Shire said Tuesday it had received a Paragraph IV Notice letter from Teva Pharmaceuticals USA Inc., advising of the filing of an abbreviated new drug application (ANDA) for its amphetamine combination product, a generic version of Shire's mixed amphetamine salts product, Adderall XR.

Shire received previously Paragraph IV Notice letters from Barr Laboratories Inc., Impax Laboratories Inc. and Colony Pharmaceuticals...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.